Daniela Bota, MD of UC Irvine Health discusses a phase II clinical trial called the CEVOREM study, which focused on everolimus and octreotide in patients with meningioma. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.
Abstract 2011: A Phase II of Everolimus and Octreotide for Patients with Refractory and Documented Progressive Meningioma (CEVOREM)
Advertisement